The innovative drug sector is warming up, and the Huaxia Science and Technology Innovation Medical ETF has increased by a total of 11.62% in the past week.

How does AI · Rongchang Biotech’s international cooperation promote the performance of the Sci-Tech Innovation Medical ETF?

As of 14:19 on April 3, 2026, the Shanghai Sci-Tech Innovation Board Biopharmaceutical Index (000683) declined by 1.90%. In terms of constituent stocks, gains and losses were mixed, with Hao Ou Bo leading with a 3.40% increase, Huiyu Pharmaceutical rising by 2.71%, and Sansheng Guojian up by 0.79%; Chengdu Lead led the decline with a 5.39% drop, Sainuo Medical fell by 4.98%, and Nuoweizan decreased by 4.19%. The Huaxia (588130) Sci-Tech Innovation Medical ETF has increased by a total of 11.62% over the past week.

In terms of news, Rongchang Biotech’s core products Taltz and Vedicitumab achieved domestic commercialization revenue of 2.27B yuan (+33.67%) in 2025, with gross profit margin rising to 84.3%, and sales expense ratio decreasing by 6.9 percentage points year-on-year, continuously optimizing profitability quality. The company has reached a global licensing agreement for RC148 with AbbVie, receiving a $650 million upfront payment and milestone payments up to $4.95 billion; Taltz has also been licensed to Vor Bio for global development, with the two collaborations totaling potential total value exceeding $5 billion, highlighting the high recognition of its technology platform by top international pharmaceutical companies.

CICC Securities pointed out that in March 2026, the innovative drug sector rebounded strongly, mainly benefiting from the valuation returning to a reasonably low level after prior substantial correction, combined with growth capital switching caused by the correction of AI-related tech stocks, as well as the continuous catalysis from the realization of annual reports and BD transactions of leading companies. Currently, the A+H shares of innovative drugs and the CXO sector are entering a dense period of performance disclosures, with leading companies’ results initially validating the sector’s recovery trend; at the same time, key clinical data readouts for AACR 2026 and ASCO 2026 are imminent, and domestic innovative drugs are accelerating from “follow-on” to leading globally.

Regarding liquidity, the Huaxia Sci-Tech Innovation Medical ETF had a turnover rate of 10.19% during intraday trading, with a transaction volume of 6.2336 million yuan, indicating active market trading. Looking at a longer period, as of April 2, the Huaxia Sci-Tech Innovation Medical ETF’s average daily transaction volume over the past week was 9.4516 million yuan.

Data shows that as of March 31, 2026, the top ten weights in the Shanghai Sci-Tech Innovation Board Biopharmaceutical Index were United Imaging Healthcare, BeiGene, Erythropoietin, BaiLi Tianheng, Rongchang Biotech, Huitai Medical, Junshi Biosciences, Zeking Pharmaceuticals, Borui Medicine, and Yirui Technology, collectively accounting for 48.91% of the total weight.